DrugPatentWatch Database Preview
TRIESENCE Drug Profile
or, see our see our flat-rate plans
Which patents cover Triesence, and what generic alternatives are available?
This drug has twenty-three patent family members in nineteen countries.
The generic ingredient in TRIESENCE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Eighty-six suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Summary for TRIESENCE
| International Patents: | 23 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 4 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | TRIESENCE at DailyMed |
Pharmacology for TRIESENCE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for TRIESENCE
US Patents and Regulatory Information for TRIESENCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novartis Pharms Corp | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novartis Pharms Corp | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
